Potassium Metaphosphate → (E)-1-(4-(5-(But-1-enyl)-1-ethylindolin-6-ylsulfonylcarbamoyl)-2-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)phenyl)-N,N-dibutyl-4-chloro-5-methyl-1H-pyrazole-3-carboxamide

HRID 528849ノート

反応式

HRID 528849 の反応式
Br[C:2]1[CH:3]=[C:4]2[C:8](=[CH:9][C:10]=1[S:11]([NH:14][C:15]([C:17]1[CH:22]=[CH:21][C:20]([N:23]3[C:27]([CH3:28])=[C:26]([Cl:29])[C:25]([C:30]([N:32]([CH2:37][CH2:38][CH2:39][CH3:40])[CH2:33][CH2:34][CH2:35][CH3:36])=[O:31])=[N:24]3)=[C:19]([C:41]([N:43]3[CH2:52][CH2:51][C:50]4[C:45](=[CH:46][CH:47]=[CH:48][CH:49]=4)[CH2:44]3)=[O:42])[CH:18]=1)=[O:16])(=[O:13])=[O:12])[N:7]([CH2:53][CH3:54])[CH2:6][CH2:5]2.[CH:55](/B(O)O)=[CH:56]\[CH2:57][CH3:58].[O-]P(=O)=O.[K+]>O1CCOCC1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd].C(P(C(C)(C)C)[C-]1C=CC=C1)(C)(C)C.[C-]1(P(C(C)(C)C)C(C)(C)C)C=CC=C1.[Fe+2]>[CH:55](/[C:2]1[CH:3]=[C:4]2[C:8](=[CH:9][C:10]=1[S:11]([NH:14][C:15]([C:17]1[CH:22]=[CH:21][C:20]([N:23]3[C:27]([CH3:28])=[C:26]([Cl:29])[C:25]([C:30]([N:32]([CH2:37][CH2:38][CH2:39][CH3:40])[CH2:33][CH2:34][CH2:35][CH3:36])=[O:31])=[N:24]3)=[C:19]([C:41]([N:43]3[CH2:52][CH2:51][C:50]4[C:45](=[CH:46][CH:47]=[CH:48][CH:49]=4)[CH2:44]3)=[O:42])[CH:18]=1)=[O:16])(=[O:12])=[O:13])[N:7]([CH2:53][CH3:54])[CH2:6][CH2:5]2)=[CH:56]\[CH2:57][CH3:58]

参加物

7

反応物 3

HCID 16133895Potassium MetaphosphateHCID 219091321-Butenylboronic acidHCID 710625451-(4-(5-bromo-1-ethylindolin-6-ylsulfonylcarbamoyl)-2-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)phenyl)-N,N-dibutyl-4-chloro-5-methyl-1H-pyrazole-3-carboxamide

生成物 1

HCID 86718889(E)-1-(4-(5-(But-1-enyl)-1-ethylindolin-6-ylsulfonylcarbamoyl)-2-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)phenyl)-N,N-dibutyl-4-chloro-5-methyl-1H-pyrazole-3-carboxamide収率 71.2%

試薬・触媒・溶媒 3

HCID 9811564Bis(dibenzylideneacetone)palladium触媒HCID 12976736Bis(ditert-butyl(cyclopenta-2,4-dien-1-yl)phosphane);iron(2+)触媒HCID 312751,4-Dioxane溶媒

反応条件

温度
90 °C

実験手順

To a sealed tube containing 1-(4-(5-bromo-1-ethylindolin-6-ylsulfonylcarbamoyl)-2-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)phenyl)-N,N-dibutyl-4-chloro-5-methyl-1H-pyrazole-3-carboxamide (Example 71, 16 mg, 0.019 mmol) in dioxane (1.0 mL) was added (E)-but-1-enylboronic acid (8 mg, 0.076 mmol), Pd2(dba)3 (9 mg, 10 μmol), 1,1′-bis(di-tert-butylphosphino)ferrocene (9 mg, 0.019 mmol) and potassium metaphosphate (5 mg, 0.038 mmol). The reaction mixture was purged with nitrogen for 1 min and then heated at 90° C. for 16 h. The reaction mixture was then diluted with EtOAc and 1N aq. HCl solution. The organic layer was separated, dried over MgSO4 and concentrated in vacuo. The residue was purified by preparative HPLC to give the title compound (11 mg, 64%) as a pale yellow solid after lyophilization. 1H NMR (CD3OD, 2:1 mixture of amide rotamers) δ 8.06-8.05 (m, 1H), 7.94 (br s, 1H), 7.65-7.63 (m, 1H), 7.30-7.11 (m, 6.5H), 6.93 (d, J=7.0 Hz, 0.5H), 6.05-5.95 (m, 1H), 4.75-4.50 (m, 2H), 3.95-3.55 (m, 1H), 3.49-3.41 (m, 2H), 3.25 (t, J=6.8 Hz, 2H), 3.15-3.10 (m, 2H), 3.00-2.96 (m, 3H), 2.90-2.65 (m, 2H), 2.33 (s, 2H), 2.28 (s, 1H), 2.21-2.18 (m, 2H), 1.58-1.02 (m, 11 H), 1.03-0.95 (m, 5H), 0.93-0.87 (m, 3H), 0.77 (t, J=7.3 Hz, 2H), 0.69 (t, J=7.4 Hz, 1H); MS(ESI+) m/z 813.3 (M+H)+.

後処理

  1. customThe reaction mixture was purged with nitrogen for 1 min
  2. additionThe reaction mixture was then diluted with EtOAc and 1N aq. HCl solution
  3. customThe organic layer was separated
  4. dry with materialdried over MgSO4
  5. concentrationconcentrated in vacuo
  6. customThe residue was purified by preparative HPLC

出典と根拠

ORDレコード
ord-3a823cfc73e34b979eadb4eb48ce05d7
出典データセット
uspto-grants-2016_05
特許番号
US09346795B2

反応ノート

読み込み中…